Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
384 studies found for:    "primary myelofibrosis"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Peginterferon alfa-2a
2 Suspended Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Condition: Primary Myelofibrosis
Interventions: Drug: Imetelstat 9.4 milligram/kilogram (mg/kg);   Drug: Imetelstat 4.7 mg/kg
3 Terminated
Has Results
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
Condition: Primary Myelofibrosis
Intervention: Drug: Ruxolitinib
4 Completed Thalidomide in Treating Patients With Myelofibrosis
Condition: Primary Myelofibrosis
Interventions: Drug: thalidomide;   Other: laboratory biomarker analysis
5 Withdrawn A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
Condition: Primary Myelofibrosis
Intervention: Biological: Pacritinib
6 Completed Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: APLIDIN (plitidepsin)
7 Active, not recruiting
Has Results
Decitabine in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: Decitabine;   Other: Laboratory Biomarker Analysis
8 Recruiting P1101 in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Other: Laboratory Biomarker Analysis;   Biological: PEG-Proline-Interferon Alfa-2b;   Other: Quality-of-Life Assessment
9 Recruiting Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg
Condition: Myelofibrosis
Interventions: Drug: Ruxolotinib;   Drug: peg-IFN alpha -2a
10 Active, not recruiting
Has Results
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence
Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide 0.5 mg;   Drug: Placebo
11 Recruiting Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
12 Completed A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: SAR302503 (TG101348)
13 Completed
Has Results
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Drug: Ruxolitinib
14 Recruiting Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Condition: Myelofibrosis
Intervention:
15 Active, not recruiting Lenalidomide for Patients With Myelofibrosis (MF)
Condition: Myelofibrosis
Interventions: Drug: Lenalidomide;   Drug: Prednisone
16 Completed
Has Results
A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
Condition: Primary Myelofibrosis (MF)
Intervention: Drug: Ruxolitinib
17 Recruiting JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Ruxolotinib
18 Recruiting Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Condition: Myelofibrosis
Interventions: Drug: Panobinostat;   Drug: Ruxolitinib
19 Not yet recruiting Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Other: Hematopoietic Stem Cell Transplant
20 Recruiting JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Momelotinib;   Drug: Mycophenolate Mofetil;   Drug: Pacritinib;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.